Yinjia Bio Honored as One of 'Top 30 Innovators in China’s Precision Diagnostics Industry 2026' Amid IPO Filing

In 2026, amidst industry shifts characterized by a tightening financing environment and market valuation corrections in the precision diagnostics sector, YINJIA BIOSCIENCES has remained steadfast in its core philosophy of “long-termism + specialized深耕 (deep cultivation).” Focusing on achieving self-sufficiency and control over high-end upstream core raw materials previously reliant on imports, the company has upheld its belief that “innovation builds core competitiveness,” continuously increasing investment in technological breakthroughs and product iteration. Leveraging its AI-driven protein design and cell-free rapid prototyping validation platform, YINJIA BIOSCIENCES has consistently advanced the industrialization of new targets and novel biomarkers. Its independently developed portfolio of more than ten diagnostic-grade protein raw materials matches the performance of top international brands, providing domestic diagnostic enterprises with a secure and efficient supply chain guarantee.

Precise diagnosis is the cornerstone of precision medicine, and the self-sufficiency and controllability of core raw materials and key reagents directly determine the performance and accessibility of diagnostic products. Winning the Golden Ding Award not only affirms YINJIA BIOSCIENCES' resilience and technological innovation capabilities in navigating industry cycles but also highly recognizes the company's role as a "value discoverer" and "long-term cultivator" in the precision diagnostics industry, reflecting dual endorsements from both the industrial and capital sectors regarding the company's technical strength and commercial value.

Dr. Wu Yifei, Founder of YINJIA BIOSCIENCES“The development of traditional raw materials for precision diagnostics is constrained by the cycle and bottlenecks of cell culture, whereas our micro-scale cell-free expression system is breaking this boundary. It makes ‘design-to-result’ a reality—completing the entire process from gene sequence to protein verification within hours, thereby accelerating the iteration speed of diagnostic products by an order of magnitude. This technology holds the promise of simplifying complex laboratory tests into portable, low-cost point-of-care diagnostic solutions, truly enhancing the accessibility of precision medicine at the grassroots level. YINJIA BIOSCIENCES will continue to act as a technological disruptor, injecting foundational innovative momentum into the precision diagnostics industry.”

The Golden Ding List, jointly launched by CHC, the Medical Device and Precision Medicine Industry & Investment Alliance, and Shangtu Consulting, features comprehensive professional evaluation by its review committee, aiming to recognize industry entities and capital forces that have made outstanding contributions to the field of precision diagnostics over the past year.